Eurofins Fact Sheet
Eurofins Scientific is an international life sciences company which provides a unique range of analytical testing services to clients across multiple industries. The Group believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics and discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the significant emerging players in specialty clinical diagnostic testing in Europe and the USA.
Eurofins Scientific was founded in 1987 with 10 employees to market the SNIF-NMR® technology, a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.
Today the Eurofins Group is a leading provider of analytical services with :
- an international network of over 310 laboratories across 39 countries in Europe, North and South America and Asia-Pacific
- 27,000 staff
- a portfolio of over 130,000 analytical methods
- more than 150 million assays performed each year to establish the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as carry out human diagnostic services.
Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins' sales have increased by 37% each year (in compound average) to over EUR 1.950 billion in 2015.
Between the Initial Public Offering on 24 October 1997 (€1.83) and 30 June 2016 (€333.60), Eurofins’ share price has multiplied by 182x, an annual average increase of 32% (against 3% for the SBF 120, 2% for the CAC 40 and 6% for the Nasdaq over the same period).
In 2015, Eurofins achieved its mid-term objective set in 2012 of generating EUR 2bn annual revenues by 2017, two years early with EUR 2.24bn pro-forma revenues in 2015 (EUR 1.95bn on a reported basis). The Group's ability to execute on its mid-term plan reflects the benefits of both past and ongoing investments to put together the most comprehensive portfolio of analytical methods and the most modern, state-of-the-art laboratory network that allows the Group to provide best-in-class analytical services to the markets it serves in the most efficient manner. Having consistently invested at higher rate than any of its large peers in the testing industry, Eurofins boasts a very modern, streamlined network of laboratories uniquely capable of providing high quality analyses at a reasonable cost. In 2015 alone, the Group added 55,000m2 of world class laboratory surface to its network, and plans another 120,000m2 additional capacity between 2016 and 2017.
Eurofins has undergone several previous intense investment phases. The first cycle saw Eurofins expand its technological portfolio and secure market leadership in food testing in several European countries; the second cycle expanded the Group's geographical footprint and established the Group as a global reference in laboratory testing of food, the environment and pharmaceutical products. During this phase, investments in start-ups in 15 new countries, along with focused acquisitions, substantially increased the range of Eurofins' offerings in its customers' key markets around the world. Overall, those laboratories started up by Eurofins in new markets such as India, China, Brazil, Singapore and Eastern Europe now provide an increasingly important growth engine for the Group. Between 2014 and 2017, the Group will be opening 35 new start-up laboratories to further enlarge its footprint in fast-growing markets.
Over the years, Eurofins has developed many new analytical testing methods and has participated in, or led several R&D projects to find better ways to analyse food, the environment, and pharmaceutical products. More recently, the Group has also started to leverage its world-renowned genomics expertise in the area of specialty clinical diagnostics testing to provide new human diagnostic capabilities. Drawing on its world-class Competence Centres and its expertise, Eurofins is driving growth from its market-leading portfolio of tests, outsourcing agreements and through cross-selling opportunities across its world-wide laboratory network.
Eurofins is committed to supporting its clients' objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate and supporting medical practitioners and patients with innovative diagnostic services. The Group intends to continue to develop and acquire the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
In February 2016, the Group has set the objective to achieve EUR 2.5bn of revenues and adjusted EBITDA above EUR 460m (at constant currency) in 2016, and from then on, to grow by about 12.5% per year over the medium term, including about EUR 200m per year from acquisitions, to reach revenues of EUR 4bn by 2020. In-line with this objective, Eurofins continues to position itself in markets where the Group sees current or potential tangible growth opportunities and intends to continue investing in its existing network, to maximize efficiency, and ensure long-term profitability.
|Contact and Addresses|
Florian Heupel, Group Marketing
Pamela Antay, Investor Relations